FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.
What happened
FDA did not inspect the plant; it reviewed records the company sent after FDA's August 14, 2025 request for records under section 704(a)(4) of the FD&C Act. The review found the quality unit did not properly oversee testing of talc, an ingredient in the company's OTC drug products, including tests meant to detect asbestos, a known human carcinogen that can occur with talc. FDA also found infrared test reports for talc with missing peaks and readings identical to three decimal places across two separately collected samples, which it called statistically unlikely and a data integrity concern.
What FDA found
The quality unit did not make sure products were made under CGMP or meet specifications, and did not fully investigate batches that failed to meet specifications.
21 CFR 211.22 and 21 CFR 211.192The quality unit did not make sure talc test methods and specifications were scientifically sound, and did not adequately review the contract laboratory's methods, including the test for absence of asbestos.
21 CFR 211.160(b)The company released a lot of talc that failed the identity test, because the infrared results showed only two of the three required peaks and other lot records showed no peaks at all.
21 CFR 211.84(e)Infrared data submitted for two independently collected talc samples had peak values identical to three decimal places, raising doubts about whether the reported results are authentic.
What FDA wants
Respond in writing within 15 working days describing what has been corrected and how recurrence will be prevented, or explain the delay and give a completion schedule. Separately, provide identity, assay and impurity results from retained talc lots, or asbestos testing of finished batches, within 30 calendar days.
Who should pay attention
- brands that buy finished OTC drug products from this contract manufacturer
- companies sourcing talc-containing topical drugs from India
- US importers and distributors of over-the-counter drug products
This is a summary. Read the original letter on fda.gov.